CARLSBAD, Calif., July 6, 2026 /PRNewswire/ -- Active Motif, a leading provider of epigenetics and multiomic solutions to mechanistic, translational, and clinical researchers, today announced an ...
Enhanced Genomics’ 3D multi-omics platform harnessed to rapidly identify multiple novel therapeutic targets that were undetectable using conventional genomic approaches Breakthrough demonstrates the ...
Appointment strengthens leadership team to drive strategy focused on harnessing 3D multi-omics to identify high-confidence, high-value therapeutic targets, to accelerate drug discovery CAMBRIDGE, ...
PHILADELPHIA & CARLSBAD, Calif., January 08, 2026--(BUSINESS WIRE)--Fox Chase Cancer Center and Arima Genomics, Inc., a company leveraging whole-genome sequence and structure information to provide ...
Enhanced Genomics ('Enhanced'), the biotechnology company pioneering 3D multi-omics to rapidly identify high-confidence, genetically validated drug targets for common diseases, today announced it has ...
In particular, genome-wide association studies (GWAS) have pinpointed hundreds of genes associated with disease risk, enabling the development of drugs targeting a broad range of highly prevalent ...
The genome is more than a linear code; it is a dynamic structure whose three-dimensional folding dictates how genes are regulated. Traditional sequencing technologies capture base-level variation but ...
Agreement expands Active Motif's research genomics portfolio while supporting Arima's strategic focus on its clinical diagnostics platform CARLSBAD, Calif., July 6, 2026 /PRNewswire/ -- Active Motif, ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results